Charles R Harrington Selected Research

hydromethylthionine

4/2022	HMTM-Mediated Enhancement of Brain Bioenergetics in a Mouse Tauopathy Model Is Blocked by Chronic Administration of Rivastigmine.
1/2022	Glutamatergic transmission and receptor expression in the synucleinopathy h-α-synL62 mouse model: Effects of hydromethylthionine.
1/2022	Hydromethylthionine enhancement of central cholinergic signalling is blocked by rivastigmine and memantine.
1/2021	Long-Term Hydromethylthionine Treatment Is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-Symptomatic P301S MAPT Mutation Carrier.
1/2021	Proteomic Analysis of Hydromethylthionine in the Line 66 Model of Frontotemporal Dementia Demonstrates Actions on Tau-Dependent and Tau-Independent Networks.
1/2020	Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia.
1/2019	Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease.
10/2018	Cysteine-Independent Inhibition of Alzheimer's Disease-like Paired Helical Filament Assembly by Leuco-Methylthioninium (LMT).
1/2018	Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.
1/2017	A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α-Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Charles R Harrington Research Topics

Disease

29	Alzheimer Disease (Alzheimer's Disease) 04/2022 - 11/2008
6	Tauopathies 04/2022 - 02/2012
5	Atrophy 04/2022 - 01/2018
5	Parkinson Disease (Parkinson's Disease) 01/2022 - 01/2017
4	Cognitive Dysfunction 04/2022 - 01/2009
4	Dementia (Dementias) 01/2022 - 12/2009
4	Neurodegenerative Diseases (Neurodegenerative Disease) 04/2021 - 01/2017
4	Frontotemporal Dementia (Semantic Dementia) 01/2021 - 01/2020
3	Synucleinopathies 01/2022 - 01/2017
1	Amyloid Plaque 02/2021
1	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 02/2021
1	Brain Diseases (Brain Disorder) 01/2021
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2021
1	COVID-19 01/2021
1	Memory Disorders (Memory Loss) 01/2021
1	Prion Diseases (Transmissible Spongiform Encephalopathies) 01/2021
1	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 01/2021
1	Disease Progression 11/2020
1	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 01/2020
1	Motor Disorders 01/2019
1	Neuroblastoma 01/2019
1	Neurobehavioral Manifestations 01/2017

Drug/Important Bio-Agent (IBA)

17	tau Proteins (tau Protein)IBA 04/2022 - 02/2012
10	hydromethylthionineIBA 04/2022 - 01/2017
8	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2009
7	Amyloid (Amyloid Fibrils)IBA 04/2021 - 02/2012
3	alpha-SynucleinIBA 01/2022 - 12/2009
3	SynucleinsIBA 01/2021 - 01/2017
2	Peptides (Polypeptides)IBA 04/2021 - 02/2021
2	PrionsIBA 01/2021 - 01/2018
2	Biomarkers (Surrogate Marker)IBA 11/2020 - 01/2020
2	Pharmaceutical PreparationsIBA 01/2020 - 01/2018
2	Cholinergic Agents (Cholinergics)IBA 01/2020 - 01/2009
1	Rivastigmine (Exelon)FDA LinkGeneric 04/2022
1	Mesylates (Mesylate)IBA 01/2022
1	Glial Fibrillary Acidic ProteinIBA 01/2021
1	AngiotensinsIBA 01/2021
1	MCOIBA 01/2021
1	Matrix Metalloproteinases (MMPs)IBA 01/2021
1	MetalsIBA 01/2021
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2021
1	Biological ProductsIBA 11/2020
1	Memantine (Namenda)FDA Link 01/2020
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 01/2020
1	Cysteine (L-Cysteine)FDA Link 10/2018
1	Glucose (Dextrose)FDA LinkGeneric 01/2018
1	DisulfidesIBA 11/2017
1	Methylene Blue (Methylthioninium Chloride)FDA Link 12/2016
1	S100 Calcium Binding Protein A6IBA 05/2013
1	Carrier Proteins (Binding Protein)IBA 05/2013
1	SNARE Proteins (SNAREs)IBA 12/2009
1	Qa-SNARE Proteins (Syntaxin)IBA 12/2009
1	thiazin redIBA 11/2008
1	Coloring Agents (Dyes)IBA 11/2008
1	Amyloid beta-PeptidesIBA 11/2008

Therapy/Procedure

9	Therapeutics 04/2022 - 04/2014
2	Activities of Daily Living (ADL) 01/2018 - 12/2016